Key facts
- It has raised $8.3M; the latest was Later Stage VC ($7.0M) in Jul 2025.
- Notable investors include European Innovation Council, Oost NL, Noaber Ventures, VGZ Zorgverzekeraar, Accenture Innovation Awards — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Plasmacure
- ·The full record, as it builds
Funding rounds
No funding rounds for Plasmacure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Plasmacure
Developer of a cold plasma technology intended to prevent amputation, thus helping in the treatment of wounds. The company's technology stimulates healing by killing bacteria, stimulating cell proliferation, and improving blood circulation, with a focus on diabetic foot wounds, kills bacteria and improves microcirculation, enabling doctors to decrease the risk of amputation and increase the quality of life for patients.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Founded
- 2013
- Employees
- 10
- Website
- plasmacure.nl/
- Ownership
- Privately Held (backing)
Plasmacure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Plasmacure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Plasmacure in its N-PORT filings yet. We sweep new filings monthly.